Literature DB >> 14722708

Case report: Successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine.

Jaskaran Singh, Carlos A Zarate, Andrew D Krystal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14722708     DOI： 10.1007/s00213-003-1756-8

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN： 0033-3158            Impact factor:   4.530


× No keyword cloud information.
  8 in total

Review 1.  Advances in the pharmacologic treatment of bipolar depression.

Authors:  Paul E Keck; Erik B Nelson; Susan L McElroy
Journal:  Biol Psychiatry       Date:  2003-04-15       Impact factor: 13.382

2.  A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group.

Authors:  J R Calabrese; C L Bowden; G S Sachs; J A Ascher; E Monaghan; G D Rudd
Journal:  J Clin Psychiatry       Date:  1999-02       Impact factor: 4.384

3.  Selective depression of low-release probability excitatory synapses by sodium channel blockers.

Authors:  M Prakriya; S Mennerick
Journal:  Neuron       Date:  2000-06       Impact factor: 17.173

Review 4.  The risk of suicide in patients with bipolar disorders.

Authors:  S G Simpson; K R Jamison
Journal:  J Clin Psychiatry       Date:  1999       Impact factor: 4.384

Review 5.  Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management.

Authors:  Joseph R Calabrese; John R Sullivan; Charles L Bowden; Trisha Suppes; Joseph F Goldberg; Gary S Sachs; Melvin D Shelton; Frederick K Goodwin; Mark A Frye; Vivek Kusumakar
Journal:  J Clin Psychiatry       Date:  2002-11       Impact factor: 4.384

6.  Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology.

Authors:  G M Goodwin
Journal:  J Psychopharmacol       Date:  2003-06       Impact factor: 4.153

Review 7.  Antidepressants in bipolar disorder: the case for caution.

Authors:  S Nassir Ghaemi; Douglas J Hsu; Federico Soldani; Frederick K Goodwin
Journal:  Bipolar Disord       Date:  2003-12       Impact factor: 6.744

8.  An open-label trial of riluzole in patients with treatment-resistant major depression.

Authors:  Carlos A Zarate; Jennifer L Payne; Jorge Quiroz; Jonathan Sporn; Kirk K Denicoff; David Luckenbaugh; Dennis S Charney; Husseini K Manji
Journal:  Am J Psychiatry       Date:  2004-01       Impact factor: 18.112
  8 in total
  8 in total

1.  Rechallenge with lamotrigine after a rash: a prospective case series and review of the literature.

Authors:  Chris B Aiken; Carolyn Orr
Journal:  Psychiatry (Edgmont)       Date:  2010-05

2.  White Matter Microstructure in Bipolar Disorder Is Influenced by the Interaction between a Glutamate Transporter EAAT1 Gene Variant and Early Stress.

Authors:  Sara Poletti; Irene Bollettini; Cristina Lorenzi; Alice Vitali; Silvia Brioschi; Alessandro Serretti; Cristina Colombo; Francesco Benedetti
Journal:  Mol Neurobiol       Date:  2018-05-22       Impact factor: 5.590

3.  Influence of an interaction between lithium salts and a functional polymorphism in SLC1A2 on the history of illness in bipolar disorder.

Authors:  Sara Dallaspezia; Sara Poletti; Cristina Lorenzi; Adele Pirovano; Cristina Colombo; Francesco Benedetti
Journal:  Mol Diagn Ther       Date:  2012-10       Impact factor: 4.074

4.  Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice.

Authors:  Shannon L Gourley; Jonathan W Espitia; Gerard Sanacora; Jane R Taylor
Journal:  Psychopharmacology (Berl)       Date:  2011-07-21       Impact factor: 4.530

Review 5.  Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder.

Authors:  Paul Grant; Jane Y Song; Susan E Swedo
Journal:  J Child Adolesc Psychopharmacol       Date:  2010-08       Impact factor: 2.576

Review 6.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

Review 7.  Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder.

Authors:  Christopher Pittenger; John H Krystal; Vladimir Coric
Journal:  NeuroRx       Date:  2006-01

Review 8.  Riluzole in psychiatry: a systematic review of the literature.

Authors:  Carlos A Zarate; Husseini K Manji
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-09       Impact factor: 4.481
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.